0 1 Yonsei ro

Seodaemun gu, South Korea

0 1 Yonsei ro

Seodaemun gu, South Korea
SEARCH FILTERS
Time filter
Source Type

Park H.J.,0 1 Yonsei ro | Cha Y.-J.,Yonsei University | Kim S.H.,0 1 Yonsei ro | Kim A.,0 1 Yonsei ro | And 2 more authors.
Tuberculosis and Respiratory Diseases | Year: 2017

Background: Although the World Health Organization (WHO) classification of lung squamous cell carcinoma (SCC) was revised in 2015, its clinical implications for lung SCC subsets remain unclear. We investigated whether the morphologic characteristics of lung SCC, including keratinization, were associated with clinical parameters and clinical outcome of patients. Methods: A total of 81 patients who underwent curative surgical resection of diagnosed lung SCC, were enrolled in this study. Attributes such as keratinization, tumor budding, single cell invasion, and nuclear size within the tumor, as well as immunohisto chemistry of Bcl-xL and pS6 expressions, were evaluated. Results: The keratinizing and nonkeratinizing subtypes did not differ with respect to age, sex, TNM stage, and morphologic parameters such as nuclear diameter, tumor budding, and single cell invasion at the tumor edge. Most patients with the keratinizing subtype (98.0%) had a history of smoking, whereas the nonkeratinizing group had a relatively higher proportion of never-smokers relative to the keratinizing group (24.0% vs. 2.0%; p=0.008, chi-square test). Expression of pS6 (a surrogate marker of mammalian target of rapamycin complex 1 [mTORC1] signaling that regulates keratinocyte differentiation), and Bcl-xL (a key anti-apoptotic molecule that may inhibit keratinization), did not correlate significantly with the presence of keratinization. Patients with the keratinizing subtype had a significantly shorter overall survival (85.2 months vs. 135.7 months, p=0.010, log-rank test), and a multivariate analysis showed that keratinization was an independent, poor prognostic factor (hazard ratio, 2.389; 95% confidence interval, 1.090-5.233; p=0.030). Conclusion: In lung SCC, keratinization is associated with a poor prognosis, and might be associated with smoking.


Han E.,0 1 Yonsei ro | Jang S.-Y.,Yonsei University | Kim G.,0 1 Yonsei ro | Lee Y.-H.,0 1 Yonsei ro | And 5 more authors.
Medicine (United States) | Year: 2016

Patients with diabetes have a higher incidence of bladder cancer; however, the association between thiazolidinedione use and bladder cancer risk has been controversial. We aimed to investigate whether pioglitazone or rosiglitazone use is associated with bladder cancer risk in patients with type 2 diabetes mellitus. This nationwide nested case-control study used data set obtained from the Korean National Health Insurance Service National Sample Cohort 2002 to 2013. Among the 47,738 patients with incident diabetes, 85 cases of newly diagnosed bladder cancer and 850 controls (1:10 matched by age, sex, index year, and diabetes diagnosis year) were recruited. Type 2 diabetes mellitus and bladder cancer were diagnosed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision code. More cases of bladder cancer were diagnosed in men (81.2%), and the stratified age peaked at 70 to 79 years old. Exclusive rosiglitazone use raised the incidence of bladder cancer (odds ratio [OR]=3.07, 95% confidence interval [CI ]=1.48-6.37). The risk of bladder cancer started to increase after less than 3 months use (OR=3.30, 95% CI=1.02-10.70) and peaked at 3 to 12 months of rosiglitazone use (OR=4.48, 95% CI=1.51-13.31). Patients were first exposed to exclusive rosiglitazone within 1 year (OR=11.74, 95% CI=2.46-56.12) and those who had consistently used it for 1 year (OR=4.48 95% CI=1.51-13.31), had higher risks of bladder cancer compared with nonthiazolidinedione users. Neither pioglitazone use nor exclusive pioglitazone use were associated with an increased incidence of bladder cancer. Rosiglitazone use is associated with an increased risk of incident bladder cancer independent of age and sex in patients with type 2 diabetes mellitus. The highest odds of bladder cancer in rosiglitazone users was seen in those with <1 year of exposure. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Loading 0 1 Yonsei ro collaborators
Loading 0 1 Yonsei ro collaborators